Literature DB >> 6990332

Group B streptococcal neonatal infection: clinical review of plans for prevention and preliminary report of quantitative antepartum cultures.

J R Bobitt, G L Brown, A H Tull.   

Abstract

The neonatal and obstetric approaches to preventing group B streptococcal neonatal infections are reviewed. Although recent reports recommend prophylactic antibiotic treatment of antepartum and intrapartum group B streptococcal carriers and low-birth-weight infants, acceptance of these schemes is not widespread. A preliminary study to evaluate the value of semiquantitative vaginal and cervical cultures of antepartum women for group B streptococcus in predicting maternal and neonatal infectious morbidity revealed: 1) 11% of the study population were carriers (group B streptococcus isolated from broth only) but only 2.8% had heavy colonization (growth in broth and on streaked plates), and 2) morbidity associated with 8 heavily colonized mothers during the current pregnancy included group B streptococcal endometritis (1 patient), neonatal sepsis (1), and readmission of a newborn for transient cyanosis (1). Two of the heavily colonized mothers were known carriers in their last pregnancy; 1 had group B streptococcal endometritis and the infant of the second developed clinical sepsis at 2 weeks of age. The clinical value of semiquantitative culture techniques requires additional investigation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6990332

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Group B streptococcal colonization patterns in mothers and their infants.

Authors:  D E Jones; K S Kanarek; D V Lim
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

2.  Evaluation of a rapid latex test for direct detection of Streptococcus agalactiae in various obstetrical and gynaecological disorders.

Authors:  R Quentin; I Dubarry; C Gignier; M Saulnier; F Pierre; A Goudeau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-01       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.